SCHEMBL14725935

SCHEMBL14725935

Cc1nc2c(N3CCOCC3)nc(Br)cn2n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.39
HPGD P15428 8/20 0.39
KDM4E B2RXH2 8/20 0.39
HSD17B10 Q99714 7/20 0.39
CYP3A4 P08684 5/20 0.39
CRHR1 P34998 1/20 0.39
POLB P06746 2/20 0.38
TSHR P16473 3/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
ALOX15 P16050 1/20 0.37
PDE10A Q9Y233 1/20 0.37
KHK P50053 1/20 0.37
KMT2A Q03164 1/20 0.36
NPY5R Q15761 1/20 0.36
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12462791 0.82 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EHSD17B10CYP3A4
SCHEMBL31038538 0.80 HTR2C (0.35)
SCHEMBL31038536 0.80 HTR2C (0.35)
SCHEMBL14725943 0.80 POLB (0.34) ALDH1A1CRHR1POLBTSHRMAPK1
SCHEMBL14725941 0.79 ALDH1A1 (0.37) ALDH1A1KDM4EPOLBTSHRMAPK1
SCHEMBL14725940 0.79 PIK3CA (0.39) ALDH1A1POLBTSHRMAPK1PIK3R1
SCHEMBL14725934 0.79 PIK3R1 (0.39) ALDH1A1KDM4ECYP3A4POLBTSHR
SCHEMBL26071904 0.78 KDM4E (0.39) ALDH1A1KDM4EPOLBMAPK1PDE10A
SCHEMBL14725937 0.78 PDE4A (0.36) ALDH1A1KDM4EPOLBTSHRMAPK1
SCHEMBL19761070 0.77 TLR9 (0.43) HPGDKDM4ECRHR1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526102-B1 Inhibitors of PI3 kinase FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) 2017-03-08 EP disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A ALDH1A1 2425/4885HPGD 2777/4885KDM4E 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.